Akèy › Sistèm Imunitè ak Twoub › Kalifòni
Etid klinik pou Sistèm Imunitè ak Twoub nan Kalifòni
18 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
Tèks ofisyèl etid la (Anglè)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- City of Hope, Duarte
- University of California, Irvine Medical Center - Hematology/Oncology, Orange
- Stanford University School of Medicine, Stanford
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07192471A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Chula Vista
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Sep 25, 2026 · NCT07541287A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- PCR Oncology, Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- Washington Health, Fremont
- ak 3 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 17, 2026 · NCT04242095(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06948318A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Northridge Clinical Trials, Northridge
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07765888A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- City of Hope, Duarte
- Stanford University, Palo Alto
- UCSF, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07075185Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of California-Irvine Medical Center, Irvine
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
- ak 1 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 1, Lancaster
- Inmagene Site 23, Los Angeles
Ap rekriteFaz 2
Laj 18 a 74 · Tout sèks · Mizajou Aug 12, 2026 · NCT07037901Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- UCLA Department of Medicine, Los Angeles
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07216443Atacicept in Multiple Glomerular Diseases
- Vera Therapeutics, Brisbane
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou Jun 26, 2026 · NCT06983028A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- University of California, San Francisco, San Francisco
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Jun 2, 2026 · NCT05787574A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Stanford University, Dept. of Dermatology, Redwood City
- UC Davis, Dept. of Dermatology, Sacramento
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 29, 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- City of Hope, Duarte
- Providence St. John's Health Center, Santa Monica
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
- USC / Norris Comprehensive Cancer Center, Los Angeles
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT03207854A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- City of Hope National Medical Center, Duarte
- Ronald Regan UCLA Medical Center, Los Angeles
- University of California Irvine Health, Orange
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 15, 2025 · NCT06619561Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Apr 29, 2022 · NCT04684602Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.